title: Tetrabenazine: Spotlight on Drug Review.
abstract: BACKGROUND
  Tetrabenazine (TBZ) is the only US Food and Drug Administration-approved drug for the treatment of chorea related to Huntington's disease and other hyperkinetic disorders. TBZ was first synthesized in 1950, and was then used for the treatment of psychosis. But later its potential in treating hyperkinetic disorders was proved by its ability to block vesicular monoamine transporters 2 and deplete monoamine stores. There is still lack of awareness about the therapeutic potential of this drug.
  
  
  CONCLUSIONS
  TBZ had been approved only for the treatment of chorea, but several clinical studies have been conducted by different research groups and it was concluded that TBZ is effective in various other conditions such as tardive dyskinesia, dystonia, tics, and Tourette's syndrome, thus, highlighting the need for further clinical trials in these conditions.
  
  
  CONCLUSIONS
  The intention of this review is to sum up the information regarding chemistry, mechanism of action, pharmacokinetics, interactions, contraindications, adverse effects, and clinical efficacy of TBZ in diseases other than Huntington's chorea.
authors.affiliation: Department of Pharmacology ISF College of Pharmacy, Moga, India.
authors.forename: Navneet
authors.initials: N
authors.lastname: Kaur
authors.affiliation: Department of Pharmacology ISF College of Pharmacy, Moga, India.
authors.forename: Puneet
authors.initials: P
authors.lastname: Kumar
authors.affiliation: Department of Pharmacology ISF College of Pharmacy, Moga, India.
authors.forename: Sumit
authors.initials: S
authors.lastname: Jamwal
authors.affiliation: Department of Pharmacology ISF College of Pharmacy, Moga, India.
authors.forename: Rahul
authors.initials: R
authors.lastname: Deshmukh
authors.affiliation: Department of Pharmacognosy, ISF College of Pharmacy, Moga, India.
authors.forename: Vinod
authors.initials: V
authors.lastname: Gauttam
keywords: Basal ganglia; Chorea; Huntington's chorea; Treatment